Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells

Anita T. Tandle, Chiara Mazzanti, H. Richard Alexander, David D. Roberts, Steven K. Libutti

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the current study we used microarray (MA) analysis to examine gene expression changes in human umbilical vein endothelial cells (HUVEC) exposed to the tumor-derived cytokine, endothelial monocyte-activating polypeptide-II (EMAP-II). HUVEC treated with EMAP-II for 0.5, 1, 2, 4 and 8 h, were analyzed using 10K cDNA arrays. Our results demonstrated that changes in gene expression of <0.5 and >2 fold were seen for 69 genes and the majority of gene changes occurred early. Validation of MA analysis for 10 genes by real time RT-PCR, demonstrated the gene changes to be consistent and specific to HUVEC when compared to human fibroblasts treated with EMAP-II. Among these genes, downregulated in ovarian cancer 1 (DOC1) gene was studied further because of its possible role in EMAP-II induced cytoskeletal remodeling. DOC1 expression was silenced using small interfering RNA. SiRNA to DOC1 completely abolished EMAP-II stimulated gene expression of DOC1. Silencing of DOC1 gene expression reversed the modulatory effect of EMAP-II on 4 other genes, suggesting that DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells.

Original languageEnglish (US)
Pages (from-to)347-358
Number of pages12
JournalCytokine
Volume30
Issue number6
DOIs
StatePublished - Jun 21 2005
Externally publishedYes

Fingerprint

Endothelial cells
Gene expression
Ovarian Neoplasms
Endothelial Cells
Genes
Down-Regulation
Gene Expression
Human Umbilical Vein Endothelial Cells
Neoplasm Genes
Microarray Analysis
Microarrays
Fibroblasts
small inducible cytokine subfamily E, member 1
Oligonucleotide Array Sequence Analysis
Small Interfering RNA
Tumors
Real-Time Polymerase Chain Reaction
Complementary DNA
Cytokines
Neoplasms

Keywords

  • DOC1
  • EMAP-II
  • Endothelial cells
  • Microarray analysis
  • SiRNA

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Immunology
  • Immunology and Allergy

Cite this

Tandle, A. T., Mazzanti, C., Alexander, H. R., Roberts, D. D., & Libutti, S. K. (2005). Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. Cytokine, 30(6), 347-358. https://doi.org/10.1016/j.cyto.2005.01.020

Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. / Tandle, Anita T.; Mazzanti, Chiara; Alexander, H. Richard; Roberts, David D.; Libutti, Steven K.

In: Cytokine, Vol. 30, No. 6, 21.06.2005, p. 347-358.

Research output: Contribution to journalArticle

Tandle, AT, Mazzanti, C, Alexander, HR, Roberts, DD & Libutti, SK 2005, 'Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells', Cytokine, vol. 30, no. 6, pp. 347-358. https://doi.org/10.1016/j.cyto.2005.01.020
Tandle, Anita T. ; Mazzanti, Chiara ; Alexander, H. Richard ; Roberts, David D. ; Libutti, Steven K. / Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. In: Cytokine. 2005 ; Vol. 30, No. 6. pp. 347-358.
@article{c4838f88e62b41c6b9525252d8684ed6,
title = "Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells",
abstract = "In the current study we used microarray (MA) analysis to examine gene expression changes in human umbilical vein endothelial cells (HUVEC) exposed to the tumor-derived cytokine, endothelial monocyte-activating polypeptide-II (EMAP-II). HUVEC treated with EMAP-II for 0.5, 1, 2, 4 and 8 h, were analyzed using 10K cDNA arrays. Our results demonstrated that changes in gene expression of <0.5 and >2 fold were seen for 69 genes and the majority of gene changes occurred early. Validation of MA analysis for 10 genes by real time RT-PCR, demonstrated the gene changes to be consistent and specific to HUVEC when compared to human fibroblasts treated with EMAP-II. Among these genes, downregulated in ovarian cancer 1 (DOC1) gene was studied further because of its possible role in EMAP-II induced cytoskeletal remodeling. DOC1 expression was silenced using small interfering RNA. SiRNA to DOC1 completely abolished EMAP-II stimulated gene expression of DOC1. Silencing of DOC1 gene expression reversed the modulatory effect of EMAP-II on 4 other genes, suggesting that DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells.",
keywords = "DOC1, EMAP-II, Endothelial cells, Microarray analysis, SiRNA",
author = "Tandle, {Anita T.} and Chiara Mazzanti and Alexander, {H. Richard} and Roberts, {David D.} and Libutti, {Steven K.}",
year = "2005",
month = "6",
day = "21",
doi = "10.1016/j.cyto.2005.01.020",
language = "English (US)",
volume = "30",
pages = "347--358",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells

AU - Tandle, Anita T.

AU - Mazzanti, Chiara

AU - Alexander, H. Richard

AU - Roberts, David D.

AU - Libutti, Steven K.

PY - 2005/6/21

Y1 - 2005/6/21

N2 - In the current study we used microarray (MA) analysis to examine gene expression changes in human umbilical vein endothelial cells (HUVEC) exposed to the tumor-derived cytokine, endothelial monocyte-activating polypeptide-II (EMAP-II). HUVEC treated with EMAP-II for 0.5, 1, 2, 4 and 8 h, were analyzed using 10K cDNA arrays. Our results demonstrated that changes in gene expression of <0.5 and >2 fold were seen for 69 genes and the majority of gene changes occurred early. Validation of MA analysis for 10 genes by real time RT-PCR, demonstrated the gene changes to be consistent and specific to HUVEC when compared to human fibroblasts treated with EMAP-II. Among these genes, downregulated in ovarian cancer 1 (DOC1) gene was studied further because of its possible role in EMAP-II induced cytoskeletal remodeling. DOC1 expression was silenced using small interfering RNA. SiRNA to DOC1 completely abolished EMAP-II stimulated gene expression of DOC1. Silencing of DOC1 gene expression reversed the modulatory effect of EMAP-II on 4 other genes, suggesting that DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells.

AB - In the current study we used microarray (MA) analysis to examine gene expression changes in human umbilical vein endothelial cells (HUVEC) exposed to the tumor-derived cytokine, endothelial monocyte-activating polypeptide-II (EMAP-II). HUVEC treated with EMAP-II for 0.5, 1, 2, 4 and 8 h, were analyzed using 10K cDNA arrays. Our results demonstrated that changes in gene expression of <0.5 and >2 fold were seen for 69 genes and the majority of gene changes occurred early. Validation of MA analysis for 10 genes by real time RT-PCR, demonstrated the gene changes to be consistent and specific to HUVEC when compared to human fibroblasts treated with EMAP-II. Among these genes, downregulated in ovarian cancer 1 (DOC1) gene was studied further because of its possible role in EMAP-II induced cytoskeletal remodeling. DOC1 expression was silenced using small interfering RNA. SiRNA to DOC1 completely abolished EMAP-II stimulated gene expression of DOC1. Silencing of DOC1 gene expression reversed the modulatory effect of EMAP-II on 4 other genes, suggesting that DOC1 might play a role in mediating some of the effects of EMAP-II on endothelial cells.

KW - DOC1

KW - EMAP-II

KW - Endothelial cells

KW - Microarray analysis

KW - SiRNA

UR - http://www.scopus.com/inward/record.url?scp=20344377898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344377898&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2005.01.020

DO - 10.1016/j.cyto.2005.01.020

M3 - Article

C2 - 15935955

AN - SCOPUS:20344377898

VL - 30

SP - 347

EP - 358

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 6

ER -